Insulin analogs and premixed insulin analogs, flexible insulin regimens, continuous subcutaneous insulin infusion with an insulin pump, and the recently approved agents that mimic amylin and GLP activity can provide the means for more closely replicating the normal physiologic profile of insulin secretion.
A recent article in Diabetes Care (1999; 22:1,584) reported an episode of diabetic acidosis in a 32-year-old Type 1 diabetic using continuous subcutaneous insulin infusion following her first experi- ence using a sauna.
The latest updates include: --Design and development of a product section, as well as an educational page about Continuous Subcutaneous Insulin Infusion (CSII) therapy, an intensive insulin therapy for diabetes that is often called insulin pump therapy; --Implementation of a Flash movie, providing an overview of the OmniPod Insulin Management System; --Creation of a Flash user interface to select and play streaming videos; --Downloads and caching of user-selected videos, instead of all at once, saving bandwidth for the user and Insulet Corporation; --Custom spotlights to highlight the new content, with an extra spotlight on the homepage to draw attention to Insulet Corporation's Medical Design Excellence Award.
Founded in 2000, the company seeks to improve the lives of people with diabetes, and to break down the barriers to continuous subcutaneous insulin infusion (CSII) therapy, through technology and through communication with healthcare professionals and those personally afflicted.
Based on insights from diabetes patients, educators and physicians, Insulet created a new solution that integrates the proven healthcare benefits of continuous subcutaneous insulin infusion (CSII) therapy with blood glucose monitoring technology in a safe, convenient and discreet two-part system.
ADA Abstract #2770-PO: Pediatric Patients Sustain Significant Improvement in A1C Levels In the study, "Sustained Improvements in Hemoglobin A1C During Long-Term Treatment With Continuous Subcutaneous Insulin Infusion (CSII) in Pediatric Patients," 102 type 1 diabetes patients (mean age 12.
Less Hypoglycemia Seen with Pump Therapy Compared to Insulin Glargine The study, "Basal Insulin: Continuous Glucose Monitoring Reveals Less Overnight Hypoglycemia with Continuous Subcutaneous Insulin Infusion than with Glargine," was designed to compare glycemic control in patients using an insulin pump to those using injections of glargine for basal control (background insulin delivered around the clock) and insulin lispro at mealtimes.
